Choosing adjunctive glaucoma therapy

The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care

Volumn , Issue , 2010, Pages 629-641

  Whitson, Jess T ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892251671     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-76700-0_52     Document Type: Chapter

References (107)

1. Boger WP 3rd. Short-term "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28(suppl):235-242.
2. Choudhri S, Wand M, Shields MB. A comparison of dorzolamidetimolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130:832-833.
3. Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Br J Ophthalmol. 2008;92:729-734.
4. Lichter PR, Musch DC, Gillespie BW; the CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953. National Drug Code Data, July 2005. Accessed 03.04.09.
5. Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13:130-136.
6. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233-235.
7. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418-423.
8. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863-868.
9. Sherwood, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124(9):1230-1238.
10. American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern. San Francisco: American Academy of Ophthalmology. 2005 Accessed 31.01.08.
11. Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95(4):601-604.
12. Soltau JB, Zimmerman TJ. Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol. 2002;47(Suppl 1):S2-S5.
13. Lee PY, Podos SM, Severin C. Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci. 1984;25(9):1087-1093.
14. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131(1):19-24.
15. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100(9):1297-1304.
16. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2-analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
17. Camras CB, Siebold EC, Lustgarten JS, et al. Maintained reduction of intraocular pressure by prostaglandin F2-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology. 1989;96:1329-1337.
18. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of Ocular Hypotensive Action of Bimatoprost (Lumigan) in Patients with Ocular Hypertension or Glaucoma. Ophthalmology. 2004;111:1658-1662.
19. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol. 2003;135:688-703.
20. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134-142.
21. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002;47(Suppl 1):S65-S76.
22. Chrai SS, Makoid MC, Eriksen SP, et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63(3):333-338.
23. Patel SC, Spaeth GL. Compliance in patients prescribed glaucoma medications. Ophthalmic Surg. 1995;26(3):233-236.
24. Broadway DC, Grierson I, O'Brien C, et al. Adverse effects of topical antiglaucoma medication. Arch Ophthalmol. 1994;112:1437-1445.
25. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary openangle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
26. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108(11):1943-1953.
27. Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin. 2006;22(5):971-976.
28. Van Der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized trials. Ophthalmology. 2005;112:1177-1185.
29. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 2003;110(3):609-614.
30. Realini T, Fechtner RD. 56, 000 ways to treat glaucoma. Ophthalmology. 2002;109(11):1955-1956.
31. Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12(3):232-236.
32. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111(9):1627-1635.
33. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514-1517.
34. Katz LJ. Twelve-month evaluation of brimonidine-purite in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119-126.
35. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma. 2001;10(3):220-226.
36. Erdogan H, Toker I, Arici MK, et al. A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%. Jpn J Ophthalmol. 2003;47(5):473-478.
37. Mundorf T, Noecker RJ, Earl M. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2007;24:302-309.
38. Wilson RP, Kanal N, Spaeth GL. Timolol: its effectiveness in different types of glaucoma. Ophthalmology. 1979;86:43-50.
39. Rettig ES, Larsson LI, Brubaker RF. The effect of topical timolol on epinephrine-stimulated aqueous humor flow in sleeping humans. Invest Ophthalmol Vis Sci. 1994;35:554-559.
40. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138:389-395.
41. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78(12):899-902.
42. Stewart WC, Day DG, Sharpe ED, et al. Efficacy and safety of timolol solution once daily vs. timolol gel added to latanoprost. Am J Ophthalmol. 1999;128(6):692-696.
43. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma. 1999;8(1):24-30.
44. Manni G, Centofanti M, Parravano M, et al. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients. Graefe's Arch Clin Exp Ophthalmol. 2004;242(9):767-770.
45. Higginbotham EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs. monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120(7):915-922.
46. Wang R-F, Serle JB, Podos SM, et al. MK-507 (L-671, 152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991;109:1297-1299.
47. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(Suppl 2):S119-S129.
48. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 1998;126(3):400-408.
49. Arici MK, Topalkara A, Guler C. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure. Int Ophthalmol. 1998;22(1):37-42.
50. Chiselita D, Apatachioae I, Poiata I. The ocular hypotensive effect of the combination of latanoprost with dorzolamide. Oftalmologia. 1999;46(4):39-45.
51. Franks W; Brinzolamide Study Group. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 2006;22(9):1643-1649.
52. Shoji N, Ogata H, Suyama H, et al. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension: an uncontrolled, open-label study. Curr Med Res Opin. 2005;21(4):503-508.
53. Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma. 2007;16(4):352-357.
54. O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol. 2002;133(6):836-837.
55. Reis R, Queiroz CF, Santos LC, et al. A randomized, investigatormasked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28(4):552-559.
56. Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology. 2005;112(4):603-608.
57. Noecker RJ. Brimonidine purite 0.15% versus dorzolamide 2% used as adjunctive therapy to latanoprost. Presented at the annual meeting of the American Glaucoma Society, San Francisco, CA, 2007 (poster).
58. Feldman RM, Tanna AP, Gross RL, et al. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. Ophthalmology. 2007;114(7):1248-1254.
59. Hollo G, Chiselita D, Petkova N, et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary openangle glaucoma. Eur J Ophthalmol. 2006;16(6):816-823.
60. Martinez-de-la-Casa JM, Castillo A, Garcia-Feijoo J, et al. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin. 2004;20(9):1333-1339.
61. Netland PA, Michael M, Rosner SA, et al. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2003;20(1):20-30.
62. Mundorf T, Dirks M, Noecker RJ, et al. Brimonidine purite 0.15% versus timolol 0.5% as adjunctive therapy with lipids. Presented at the annual meeting of the American Glaucoma Society, Snowbird, UT, 2005.
63. Nietgen GW, Schmidt J, Hesse L, et al. Muscarinic receptor functioning and distribution in the eye: molecular basis and implications for clinical diagnosis and therapy (review). Eye. 1999;13(Pt 3a):285-300.
64. Toris CB, Zhan G-L, Zhao J, Camras CB, Yablonski ME. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol. 2001;131:722-728.
65. Fristrom B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111(5):662-665.
66. Camras CB, Wang R-F, Podos SM. Effect of pilocarpine applied before or after prostaglandin F2a on IOP in glaucomatous monkey eyes. Invest Ophthalmol Vis Sci. 1990;31:150.
67. Villumsen J, Alm A. Effect of the prostaglandin F2a analogue PhXA41 in eyes treated with pilocarpine and timolol. Invest Ophthalmol Vis Sci. 1992;33:1248.
68. Friström B, Nilsson S E G. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111:662-665.
69. Kent AR, Vroman DT, Thomas TJ, Herbert RL, Crosson CE. Interaction of pilocarpine with latanoprost in patientswith glaucoma and ocular hypertension. J Glaucoma. 1999;8:257-262.
70. Shin DH, McCracken MS, Bendel RE, et al. The additive effect of latanoprost to maximum-tolerated medications with low-dose, highdose and no pilocarpine therapy. Ophthalmology. 1999;106:386-390.
71. Rulo AH, Greve EL, Hoyng PF. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure. Ophthalmology. 1997;104(9):1503-1507.
72. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Arch Ophthalmol. 1977;95:1378-1382.
73. Wallace TR, Fraunfelder FT, Petursson GJ, Epstein DL. Decreased libido - a side effect of carbonic anhydrase inhibitor. Ann Ophthalmol. 1979;11:1563-1566.
74. Epstein RJ, Allen RC, Lunde MW. Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma. Ann Ophthalmol. 1987;19:48-50.
75. Heller I, Halevy J, Cohen S, Theodor E. Significant metabolic acidosis induced by acetazolamide: not a rare complication. Arch Intern Med. 1985;145:1815-1817.
76. Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology. 1981;88:261-265.
77. Howlett SA. Renal failure associated with acetazolamide therapy for glaucoma. South Med J. 1975;68:504-506.
78. Higenbottam T, Ogg CS, Saxton HM. Acute renal failure from the use of acetazolamide (Diamox). Postgrad Med J. 1978;54:127-128.
79. Fraunfelder FT, Meyer SM, Bagby GC Jr, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol. 1985;100:79-81.
80. Werblin TP, Pollack IP, Liss RA. Blood dyscrasias in patients using methazolamide (Neptazane) for glaucoma. Ophthalmology. 1980;87:350-354.
81. Weiss IS. Hirsutism after chronic administration of acetazolamide. Am J Ophthalmol. 1974;78:327-328.
82. Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol. 1997;115:550-553.
83. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1999;106(12 Suppl):10-16.
84. Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2003;121(4):453-457.
85. Bastien N, Psaradellis F, Sampalis J, et al. Effect of dorzolamidetimolol (Cosopt (R)) co-administered with latanoprostTM or dorzolamide-timolol alone in patients with open angle glaucoma or ocular hypertension not adequately controlled on latanoprost. Presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2006:441-B176.
86. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124(9):1230-1238.
87. Nixon DR, Hollander DA. Comparison of the efficacy and tolerability of twice-daily CombiganTM vs. Cosopt (R) fixed-combination therapies. Presented at the annual meeting of the American Academy of New Orleans, LA, 2007.
88. Hommer A; Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17(1):53-62.
89. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392-399.
90. Neelakantan A, Vaishnav HD, Iyer SA, et al. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma. 2004;13(2):130-136.
91. Babizhayev MA, Brodskaya MW, Mamedov NG, et al. Clinical, structural and molecular phototherapy effects of laser irradiation on the trabecular meshwork of human glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 1990;228(1):90-100.
92. Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001;108(4):773-779.
93. Damji KF, Bovell AM, Hodge WG, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial. Br J Ophthalmol. 2006;90(12):1490-1494.
94. Damji KF, Shah KC, Rock WJ, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty: a prospective randomised clinical trial. Br J Ophthalmol. 1999;83(6):718-722.
95. Ruderman JM, Welch DB, Smith MF, et al. A randomized study of 5-fluorouracil and filtration surgery. Am J Ophthalmol. 1987;104(3):218-224.
96. Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology. 1991;98(3):317-321.
97. Hayreh SS. Anatomy and physiology of the optic nerve head. Trans Am Acad Ophthalmol Otolaryngol. 1974;78(2): OP240-OP254.
98. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995;113(2):216-221.
99. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107(7):1287.
100. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119(12):1819-1826.
101. Leske MC, Connell AM, Wu SY, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol. 2001;119(1):89-95.
102. Leske MC, Wu S-Y, Hennis A, Honkanen R, Nemesure B. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Ophthalmology. 2008;115:85-93.
103. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47:2917-2923.
104. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41(9):2566-2573.
105. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204-1212.
106. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44(Suppl 2):S141-S145.
107. Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol. 2000; suppl 2:S155-S162.